ANTEPAR Drug Patent Profile
When do Antepar patents expire, and when can generic versions of Antepar launch?
Antepar is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in ANTEPAR is piperazine citrate. There is one drug master file entry for this compound. Additional details are available on the piperazine citrate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ANTEPAR?
- What are the global sales for ANTEPAR?
- What is Average Wholesale Price for ANTEPAR?
Summary for ANTEPAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 34 |
| Patent Applications: | 320 |
| DailyMed Link: | ANTEPAR at DailyMed |
US Patents and Regulatory Information for ANTEPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ANTEPAR | piperazine citrate | SYRUP;ORAL | 009102-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline | ANTEPAR | piperazine citrate | TABLET;ORAL | 009102-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
